{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:55:03Z","timestamp":1781564103275,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The early differential diagnosis of Parkinson\u2019s disease (PD) and atypical parkinsonian syndromes (APSs) poses challenges. The current methods, which rely on clinical assessments and single-modal biomarkers, lack sufficient sensitivity and specificity. This study aims to develop a multidimensional model integrating plasma biomarkers, clinical parameters, and neuroimaging radiomic features to improve the accuracy of differentiating PD from APS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 150 participants were enrolled in the study, including 56 healthy controls (HC), 54 patients with PD, and 40 patients with APSs. Plasma biomarkers (NFL, GFAP,\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -syn, and tau), clinical indicators (e.g., disease duration and UPDRS-III scores), and radiomic features (1,316 IBSI-standardized features) from magnetic resonance imaging scans of the midbrain and pons were collected. Core variables were screened using LASSO regression and random forest algorithms, and a multivariate logistic regression model was constructed. The performance of the model was evaluated using receiver operating characteristic curves, calibration curves, and cross-validation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma GFAP and NFL levels showed a significant gradient change: APS group (GFAP: 89.9\u202fpg.\/mL; NFL: 77.3\u202fpg.\/mL)\u202f&amp;gt;\u202fPD group (GFAP: 47.1\u202fpg.\/mL; NFL: 50.0\u202fpg.\/mL)\u202f&amp;gt;\u202fHC group (GFAP: 22.1\u202fpg.\/mL; NFL: 37.5\u202fpg.\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). The levels of\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -syn and tau in the PD and APS groups were significantly higher than those in the HC group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), but there was no difference between the two groups. Four core variables (NFL, GFAP, disease duration, and pontine voxel volume) were selected. The area under the curve (AUC) of the combined model for identifying PD and APS was 0.874 (95% confidence interval: 0.801\u20130.946), which was significantly higher than that of single variables (such as NFL alone AUC\u202f=\u202f0.653). Cross-validation confirmed the stability of the model (AUC\u202f=\u202f0.843).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This was the first study to integrate plasma NFL\/GFAP, clinical disease duration, and pontine radiomic features to construct a high-precision PD-APS differential model (AUC\u202f&amp;gt;\u202f0.87), addressing the limitations of traditional single-mode approaches. The gradient changes in GFAP and the APS-specificity of NFL serve as key biomarkers. Thus, this multidimensional framework provides a practical diagnostic tool for resource-limited scenarios.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1727812","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:33:43Z","timestamp":1768545223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Combining plasma biomarkers, clinical parameters, and neuroimaging features for differential diagnosis of Parkinson\u2019s disease and atypical parkinsonian syndromes: a multidimensional modeling approach"],"prefix":"10.3389","volume":"18","author":[{"given":"Jian","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Neurology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]},{"name":"The Second School of Clinical Medicine, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]},{"name":"School of Clinical Medicine, Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesia Surgery, Liwan Central Hospital","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglian","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zan","sequence":"additional","affiliation":[{"name":"School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangshan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University","place":["Guangzhou, Guangdong, China"]},{"name":"The Second School of Clinical Medicine, Southern Medical University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1053\/j.semnuclmed.2014.12.003","article-title":"PET\/MR in dementia and other neurodegenerative diseases","volume":"45","author":"Barthel","year":"2015","journal-title":"Semin. Nucl. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1199826","DOI":"10.3389\/fnagi.2023.1199826","article-title":"The differential diagnosis value of radiomics-based machine learning in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Bian","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00702-025-02930-2","article-title":"Fluid biomarkers in atypical parkinsonism: current state and future perspectives","volume":"132","author":"Bougea","year":"2025","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","article-title":"Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches","volume":"16","author":"Boxer","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/mds.28348","article-title":"Automated categorization of parkinsonian syndromes using magnetic resonance imaging in a clinical setting","volume":"36","author":"Chougar","year":"2021","journal-title":"Mov. Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-51140-1_11","article-title":"Progressive supranuclear palsy and corticobasal degeneration","volume":"1281","author":"Coughlin","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41531-023-00481-5","article-title":"Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy","volume":"9","author":"Guo","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"key":"ref13","first-page":"S11","article-title":"Parkinsonism: onset, progression, and mortality. 1967","volume":"57","author":"Hoehn","year":"2001","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1007\/s12035-023-03713-0","article-title":"TREM2 deficiency aggravates NLRP3 inflammasome activation and pyroptosis in MPTP-induced Parkinson\u2019s disease mice and LPS-induced BV2 cells","volume":"61","author":"Huang","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","article-title":"Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome","volume":"77","author":"Jabbari","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1007\/s00415-024-12647-z","article-title":"GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)","volume":"271","author":"Katzdobler","year":"2024","journal-title":"J. Neurol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1750-3639.1999.tb00549.x","article-title":"Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and pick\u2019s disease","volume":"9","author":"Komori","year":"1999","journal-title":"Brain Pathol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00415-025-12894-8","article-title":"Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"272","author":"Kou","year":"","journal-title":"J. Neurol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00415-025-13051-x","article-title":"Cerebrospinal fluid and blood neurofilament light chain in Parkinson\u2019s disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis","volume":"272","author":"Kou","year":"","journal-title":"J. Neurol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3349\/ymj.2000.41.2.167","article-title":"The pedunculopontine nucleus: its role in the genesis of movement disorders","volume":"41","author":"Lee","year":"2000","journal-title":"Yonsei Med. J."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fnagi.2018.00123","article-title":"Plasma biomarkers differentiate Parkinson\u2019s disease from atypical parkinsonism syndromes","volume":"10","author":"Lin","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"115266","DOI":"10.1016\/j.celrep.2025.115266","article-title":"Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson\u2019s disease via the prosaposin-GPR37-IL-6 axis","volume":"44","author":"Ma","year":"2025","journal-title":"Cell Rep."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e70274","DOI":"10.1002\/brb3.70274","article-title":"Assisted parkinsonism diagnosis using multimodal MRI-the role of clinical insights","volume":"15","author":"Meindl","year":"2025","journal-title":"Brain Behav."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1053\/j.semnuclmed.2025.03.007","article-title":"PET\/CT in movement disorders: update","volume":"55","author":"Nerattini","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/NDT.S146080","article-title":"Diagnostic challenges in multiple system atrophy","volume":"14","author":"Obelieniene","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41531-022-00392-x","article-title":"Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes","volume":"8","author":"Schr\u00f6ter","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/JPD-181568","article-title":"Diagnostic potential of multimodal MRI markers in atypical parkinsonian disorders","volume":"9","author":"Seki","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/WCO.0b013e3283632da6","article-title":"Atypical parkinsonism: an update","volume":"26","author":"Stamelou","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00702-022-02498-1","article-title":"Blood-based biomarker in Parkinson\u2019s disease: potential for future applications in clinical research and practice","volume":"129","author":"T\u00f6nges","year":"2022","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1002\/alz.14276","article-title":"Association of CSF \u03b1-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer\u2019s Disease Neuroimaging Initiative study","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The Movement Disorder Society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov. Disord."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41531-022-00431-7","article-title":"A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson\u2019s disease","volume":"8","author":"Xiang","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1038\/s41598-023-32480-0","article-title":"Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson\u2019s disease biomarkers using multiplexed single molecule counting","volume":"13","author":"Youssef","year":"2023","journal-title":"Sci. Rep."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1016\/j.acra.2024.08.016","article-title":"Accuracy of 18F-FDG PET imaging in differentiating Parkinson\u2019s disease from atypical parkinsonian syndromes: a systematic review and meta-analysis","volume":"31","author":"Zhao","year":"2024","journal-title":"Acad. Radiol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1727812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:35:16Z","timestamp":1771918516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1727812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":38,"alternative-id":["10.3389\/fnagi.2026.1727812"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1727812","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1727812"}}